Combining chemotherapy and targeted therapy for advanced biliary tract cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 2 study evaluates the effects and safety of a combined therapy using oxaliplatin and gemcitabine chemotherapy alongside Donafenib and Tislelizumab for patients with advanced biliary tract carcinoma. The study targets patients with stages III and IV of the disease, which typically have poor survival rates and limited treatment options. The combination aims to improve efficacy and safety based on prior phase I trial results that indicated promising outcomes. The study will expand on these findings by increasing the sample size to better assess the treatment's effectiveness.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years and ≤75 years;
* ECOG physical condition score: 0\~1;
* Histologically or cytologically confirmed advanced biliary tract carcinoma (including gallbladder, intrahepatic and extrahepatic cholangiocarcinoma);
* Preoperative imaging assessment of the disease stage was III/IV;
* At least one measurable lesion (according to mRECIST criteria)
* Child-Pugh classification : A or B
* The main organs function well, and the examination indicators meet the following requirements:
* Routine blood tests: Hemoglobin ≥90 g/L (no blood transfusion within 14 days);Neutrophil count ≥1.5×10\^9/L; Platelet count ≥80×10\^9/L;
* Biochemical examination: Total bilirubin ≤2×ULN (upper normal value); ALT or AST ≤ 2.5×ULN; Endogenous creatinine clearance ≥ 50 mL /min (Cockcroft-Gault formula);
* thyroid function:Thyroid function is normal, thyroid stimulating hormone TSH is defined to be within the normal range. If baseline TSH is outside the normal range, T3 and T4 can be included if they are within the normal range;
* Myocardial enzyme profile:The myocardial enzyme profile was in the normal range (if simple laboratory abnormalities that were not clinically significant as determined by the investigators could also be included);
* Estimated survival time ≥ 3 months;
* Sign the informed consent voluntarily;
* Good compliance, and family members willing to cooperate with follow-up.

Exclusion Criteria:

* Patients with other uncured malignant tumors;
* Pregnant or lactating women who are required to withdraw from the clinical trial if they become pregnant during the study period;
* Previous antitumor therapy for the disease in this study;
* Participated in clinical trials of other drugs within one month;
* Patients with a known history of other systemic serious diseases before screening;
* Obstructive jaundice (after active treatment such as biliary drainage or stent, the patients can be included in the group after the liver function returns to normal);
* Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number greater than the upper limit of normal in the clinical laboratory of the study center);
* Active HCV infected persons (HCV antibody positive with HCV RNA levels above the lower limit of detection);
* Allergic to any investigational drug or excipient;
* Long-term unhealed wounds or incomplete healing fractures;
* Previous organ transplantation history;
* Having a history of abuse of psychotropic substances and being unable to quit or having mental disorders;
* A history of immune deficiency or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
* Concomitant conditions that, in the investigator's judgment, seriously endanger the patient's safety or affect the patient's completion of the study.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Lu Wang, M.D.
• Email: w.lr@hotmail.com
• Phone: 86-18121299357

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• SYS6010 plus Enlonstobart for recurrent or metastatic nasopharyngeal cancer in patients who have not had prior systemic therapy

  This trial tests whether SYS6010 with Enlonstobart works better than Tislelizumab with gemcitabine and cisplatin for people whose recurrent or metastatic nasopharyngeal cancer has not yet received systemic treatment.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Guangzhou, Guangzhou · NCT07925021

• Neoadjuvant therapy for locally advanced low rectal cancer: adding fruquintinib to short-course radiotherapy with tislelizumab and CAPOX

  This study tests whether adding fruquintinib to short-course radiotherapy plus tislelizumab and CAPOX before surgery helps people with locally advanced low rectal cancer achieve a better tumor response.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07888309

• Tislelizumab plus Anlotinib after chemoradiotherapy in limited-stage SCLC

  This phase II trial tests whether adding tislelizumab and anlotinib after chemoradiotherapy helps people with limited-stage small cell lung cancer stay cancer-free.

  Recruiting Phase 2 Yantai Yuhuangding Hospital · Yantai, Shandong · NCT07815223

• Sacituzumab Govitecan plus Tislelizumab for advanced esophageal cancer

  This phase II study tests whether the cancer-fighting drug sacituzumab tirumotecan (SKB264) combined with tislelizumab can help adults with advanced esophageal squamous cell carcinoma that progressed after initial immunotherapy.

  Recruiting at 2 sites Phase 2 Shanghai Chest Hospital · Shanghai and 1 other locations · NCT07811752

• QLC5508 plus QL2107 vs tislelizumab plus platinum chemotherapy as first treatment for extensive-stage small cell lung cancer

  This phase 3 trial tests whether QLC5508 with QL2107 works better than tislelizumab with platinum chemotherapy for adults with untreated extensive-stage small cell lung cancer.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Shanghai · NCT07802821

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.